Tacrolimus Market Size, Share & Trends Analysis Report By Product Type (Tablets & Capsules, Injections, Others), Application (Immunosuppression, Dermatitis), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Tacrolimus Market Size & Trends

The global tacrolimus market size is expected to grow at a compound annual growth rate (CAGR) of 5.3% from 2023 to 2030. The worldwide increase in the number of transplants and a surge in immunosuppressive research and development is anticipated to fuel the growth of the market. For instance, as per the report of the United Network for Organ Sharing (UNOS), in 2022, 42,887 organ transplants were performed in the U.S.

Tacrolimus is a crucial component of organ transplant procedures since it is given to allograft patients receiving immunosuppressive medication therapy. In 2021, according to data from the Australian and New Zealand Organ Donor Registry (ANZOD), 657 kidney transplants, 171 lung transplants, 253 liver transplants, and 152 other organ transplant procedures were carried out in Australia alone. Such a rise in transplant procedures is anticipated to promote tacrolimus pharmaceutical adoption, which will ultimately fuel market expansion during the forecast period. In addition, an increase in new product launches, product approvals, and research and development activities is anticipated to accelerate market growth over the forecast period. For instance, in August 2023, Glenmark Pharmaceuticals received the ANDA approval for 0.03 percent Tacrolimus ointment.

The main factors that limit the growth of the tacrolimus market globally are side effects and the availability of alternative treatments. Tacrolimus, for instance, might have major side effects including decreased urination, discomfort or burning when urinating, pale complexion, shortness of breath, a fast heartbeat, coma (loss of consciousness for a while), etc. Tacrolimus' most frequent adverse effects include headache, nausea, diarrhea, and constipation. Additionally, the availability of tacrolimus alternative medications is anticipated to restrain market expansion. In contrast to other anti-rejection medications on the market, Nulojix is an injectable treatment. It was created as a possible Prograf (tacrolimus) replacement medicine. This medication's objective is to prevent rejection as well as harmful side effects.

Product Type Insights

Based on the product type, the global tacrolimus market is segmented into tablets and capsules, injections, and others. The tablets and capsules segment held the largest market in 2023. This is due to the fact that tablets and capsules are convenient and easy for patients to take, ensuring better compliance with medication regimens, which are crucial for immunosuppressant therapy.

Application Insights

Based on application, the market is segmented into immunosuppression, dermatitis, and others. The immunosuppression segment dominated the market in 2023 and is anticipated to continue this dominance during the forecast period. The immunosuppression drugs are essential to prevent the organ rejection in transplant recipients. The increasing number of organ transplant surgeries drives the demand for this medication in the forecast period.

End-use Insights

Based on end-use, the global tacrolimus market is segmented into hospitals, clinics, and others. The hospital segment dominated the market with the largest market share in 2023. The presence of specialized transplant centers in hospitals often results in a higher volume of transplant procedures and consequently, a greater need for tacrolimus. Also, the government programs for initiatives that promote organ transplantation and provide financial support for immunosuppressant medications can boost the demand in hospitals.

Regional Insights

North America dominated the market in 2023 owing to factors such as a rise in organ transplants, increased tacrolimus awareness, and the presence of important manufacturers in the area. For instance, the U.S. alone witnessed the performance of over 40,000 transplants in 2021, according to predictions from the Health Resources and Services Administration. In addition, there were 90,483 patients waiting for organ transplants. As a result, the patient population will use tacrolimus drugs more frequently as a result of the increased number of transplant surgeries, propelling the market's expansion in North America.

Key Companies & Market Share Insights

Key players operating in the market are Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, LEO Pharma A/S, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Panacea Biotec, Biocon Ltd., Novartis AG. The market participants are working towards new product development, M&A activities, and other strategic alliances to gain new market avenues. In August 2023, Glenmark Pharmaceuticals received the ANDA approval for 0.03 percent Tacrolimus ointment.